Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Daunoxome
2. Daunorubicin Citrate [mart.]
3. Daunorubicin Liposomal
4. 371770-68-2
5. Daunorubicin (citrate)
6. Daunorubicin Citrate [orange Book]
7. Daunorubicin Citrate Liposome
8. 5l84t2z6np
9. Daunoxome (tn)
10. (7s,9s)-9-acetyl-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;2-hydroxypropane-1,2,3-tricarboxylic Acid
11. Unii-5l84t2z6np
12. Schembl42311
13. Chembl1200475
14. Dtxsid20190659
15. Daunorubicin Citrate [who-dd]
16. 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s,10s)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
17. 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s,10s)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt)
18. Hy-108876
19. Cs-0031208
20. Daunorubicin Citrate Liposome [vandf]
21. D10787
22. Q27262517
23. 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s,10s)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
24. 5,12-naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8s,10s)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt)
Molecular Weight | 719.6 g/mol |
---|---|
Molecular Formula | C33H37NO17 |
Hydrogen Bond Donor Count | 9 |
Hydrogen Bond Acceptor Count | 18 |
Rotatable Bond Count | 9 |
Exact Mass | 719.20614871 g/mol |
Monoisotopic Mass | 719.20614871 g/mol |
Topological Polar Surface Area | 318 Ų |
Heavy Atom Count | 51 |
Formal Charge | 0 |
Complexity | 1190 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Market Place
ABOUT THIS PAGE
A Daunorubicin Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Daunorubicin Citrate, including repackagers and relabelers. The FDA regulates Daunorubicin Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Daunorubicin Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Daunorubicin Citrate supplier is an individual or a company that provides Daunorubicin Citrate active pharmaceutical ingredient (API) or Daunorubicin Citrate finished formulations upon request. The Daunorubicin Citrate suppliers may include Daunorubicin Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Daunorubicin Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Daunorubicin Citrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Daunorubicin Citrate active pharmaceutical ingredient (API) in detail. Different forms of Daunorubicin Citrate DMFs exist exist since differing nations have different regulations, such as Daunorubicin Citrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Daunorubicin Citrate DMF submitted to regulatory agencies in the US is known as a USDMF. Daunorubicin Citrate USDMF includes data on Daunorubicin Citrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Daunorubicin Citrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Daunorubicin Citrate suppliers with USDMF on PharmaCompass.
Daunorubicin Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Daunorubicin Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Daunorubicin Citrate GMP manufacturer or Daunorubicin Citrate GMP API supplier for your needs.
A Daunorubicin Citrate CoA (Certificate of Analysis) is a formal document that attests to Daunorubicin Citrate's compliance with Daunorubicin Citrate specifications and serves as a tool for batch-level quality control.
Daunorubicin Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Daunorubicin Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Daunorubicin Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Daunorubicin Citrate EP), Daunorubicin Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Daunorubicin Citrate USP).
LOOKING FOR A SUPPLIER?